Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab Monotherapy in Advanced Bladder Urothelial Carcinoma
NCT03113266Phase 2Unknown
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Apr 2017
- Primary completion
- Mar 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in bladder urothelial carcinoma, sponsored by Shanghai Junshi Biosciences Co., Ltd.. Status: unknown.
02
Drugs
toripalimab
03
Conditions
bladder urothelial carcinoma
Beyond the preview
Go deeper on NCT03113266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03113266.